Skip to main content
Home > BC Innovations > Tools

Chronological Index of : Tools

 Current Issue
  • Democratizing antibodies

    The Gates Foundation turns to industry to innovate antibody manufacturing

    With two new deals, the Gates Foundation is turning to industry for new methods in antibody manufacturing that can work in developing countries.

    Published on 9/1/2016
  • Go small or go home

    A portable manufacturing unit for single doses of biologics

    An MIT duo has coupled a small scale bioreactor with cellular engineering to produce single-dose biologics, with applications ranging from process development to the battlefield.

    Published on 8/18/2016
  • Twenty-sided therapy

    Capitalizing on the many facets of 20-sided nanoparticles

    A University of Washington team has created 20-sided protein nanoparticles that can be custom fit for vaccines or drug delivery.

    Published on 8/18/2016
  • Figure: Just a little culture

    Go small or go home Tools & Techniques Just a little culture Massachusetts Institute of Technology (MIT) scientists have coupled a state-of-the-art microbioreactor and a genetically engineered yeast strain to …

    Published on 8/18/2016
  • Table: BioCentury Product Profile

    Go small or go home Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Cell line optimized for continuous, switchable production of multiple proteins Concept …

    Published on 8/18/2016
  • Figure: Parts and particle

    Twenty-sided therapy Tools & Techniques Parts and particle In a study published in Science, researchers from the University of Washington described 10 computationally designed protein structures that successfully …

    Published on 8/18/2016
  • Table: BioCentury Product Profile

    Twenty-sided therapy Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Self-assembling protein nanoparticles Concept Programmable particles comprising …

    Published on 8/18/2016
  • Neutralizing the flu

    How NIH has streamlined the hunt for neutralizing flu antibodies

    With a new NIH finding that most people make neutralizing antibodies to the flu, the question is whether that translates better to an active or passive vaccine.

    Published on 8/11/2016
  • Figure: Grabbing flu by the stem

    Neutralizing the flu Tools & Techniques Grabbing flu by the stem In a study published in Cell, researchers from NIH's National Institute of Allergy and Infectious Diseases (NIAID) described three classes of …

    Published on 8/11/2016
  • Table: BioCentury Product Profile

    Neutralizing the flu Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Universal vaccine for influenza A Concept Prophylactic influenza A vaccine targeting a …

    Published on 8/11/2016
  • Figure: Crossing the aisle

    Best of both worlds Tools & Techniques Crossing the aisle Over the past few years, the focus of immuno-oncology R&D has expanded to include a new type of innate immune cell that straddles the innate and adaptive …

    Published on 7/28/2016
  • Figure: Natural death

    Innate harmony Tools & Techniques Natural death NK cell activity is dictated by activating and inhibitory receptors on the cell surface that work together to distinguish tumor cells from healthy cells. NK cell …

    Published on 7/28/2016
  • Table: Natural killer cell therapeutics

    Innate harmony Tools & Techniques Natural killer cell therapeutics Select natural killer (NK) cell therapies and NK cell-directed antibodies in clinical and preclinical development for cancer. There are two primary…

    Published on 7/28/2016
  • Innate harmony

    Why NK cells are the next big thing in immuno-oncology

    NK cells are becoming the new shiny tool in immuno-oncology, filling out company pipelines for their potential as alternatives or partners for CAR T cells.

    Published on 7/28/2016
  • Best of both worlds

    Why NKT cells could help or even upstage CAR T cells

    Baylor researchers are working in the sweet spot between adaptive and innate immunity to use NKT cells in immuno-oncology.

    Published on 7/28/2016
  • A new route for CARs

    Adapting CAR T technology to treat autoimmune diseases

    A UPenn team has adapted CAR T cell technology to target autoimmune cells, and believes the strategy may work as well in autoimmunity as it does in cancer, with fewer liabilities.

    Published on 7/21/2016
  • Cryo-EM a river

    As cryo-EM races forward, companies are partnering to keep up

    A rush of technical improvements are making cryo-EM an attractive choice for structure-based drug design, and companies are collaborating to catch the wave.

    Published on 7/14/2016
  • Box: New resolutions

    Cryo-EM a river Tools & Techniques New resolutions Fueled by technological improvements in cryo-electron microscopy (cryo-EM), a team at the National Cancer Institute (NCI) has been pushing the method's limitations…

    Published on 7/14/2016
  • Figure: Frozen in time

    Cryo-EM a river Tools & Techniques Frozen in time Researchers at the National Cancer Institute (NCI) have generated a composite image that illustrates how cryo-electron microscopy (cryo-EM) resolution has improved …

    Published on 7/14/2016
  • Figure: No entry

    Home is in the placenta Tools & Techniques No entry In a recent paper in Science Advances, a University of Manchester group found that a pair of tumor-targeting peptides can home to the placenta, without reaching …

    Published on 6/23/2016
  • Table: Preeclampsia pipeline

    Home is in the placenta Tools & Techniques Preeclampsia pipeline Select products in clinical and preclinical development to treat preeclampsia. At least five companies are developing therapeutics for preeclampsia, …

    Published on 6/23/2016
  • Home is in the placenta

    How tumor-targeting peptides could de-risk drug development in pregnancy

    The discovery of placenta-homing peptides that don't reach the fetus could shift the risk-reward ratio for drug development in pregnancy.

    Published on 6/23/2016
  • What GWAS will be

    Two studies help find which GWAS hits actually matter

    With a new way to identify the few functional genetic variants from thousands of hits, two groups have taken GWAS to the next level.

    Published on 6/23/2016
  • Figure: Massive screen of small changes

    What GWAS will be Tools & Techniques Massive screen of small changes Two groups from the Broad Institute of MIT and Harvard have published a pair of studies in Cell showing a massively parallel reporter assay (MPRA…

    Published on 6/23/2016
  • Figure: Massive screen of small changes

    What GWAS will be Tools & Techniques Massive screen of small changes Two groups from the Broad Institute of MIT and Harvard have published a pair of studies in Cell showing a massively parallel reporter assay (MPRA…

    Published on 6/23/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993